10401 results for 'part deliv next'

Gene Delivery · Viral VectorsLentiviral Vectors: Design, Production and Use in Gene DeliveryLentiviral vectors integrate their cargo into the host genome and transduce dividing and non-dividing cells

An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci

Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t

Platinum based cancer drugs Despite nearly 50% of all anti-cancer treatments being platinum-based, there is an urgent need to develop novel therapeutics

For decades, the fight against cancer has been a relentless battle of incremental gains. While immunotherapies like CAR-T cell therapy have offered revolutionary hope, their personalized nature, high

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An

For years, the success of CAR-T cell therapy has been a beacon of hope in the fight against blood cancers, offering remarkable remissions where other treatments have failed. Yet, solid tumors—the form

A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient

For decades, the fight against cancer has been a relentless battle of attrition, often with treatments that harm the body as much as the disease. But a new era of precision medicine is dawning, one th

Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells th

For decades, the fight against cancer has been a grueling battle of attrition, with treatments often as harsh as the disease itself. But a revolutionary approach, chimeric antigen receptor (CAR)-T cel

For decades, the brain has been considered an immune sanctuary, protected by the formidable blood-brain barrier. This intricate defense system, while vital for safeguarding our most complex organ, ha

Department of Oncology RetreatAssay Genie was honoured to sponsor and participate in the inaugural 2025 Department of Oncology Retreat, hosted by the University of Lausanne and Lausanne

Techniques · Gene DeliveryTransduction vs Transfection: Understanding Gene Delivery TechniquesTransduction and transfection are the two main routes for introducing genetic material into cells. Transdu

3D Organoid Cell Viability Assay (AKES081) effectively measures BENO model viability across different storage conditions. AKES081 detects significant viability differences, particularly

We know it gets tiring being in the lab every day, especially with the evenings getting darker and gloomier. So, to get you in the festive spirit, we're holding a competition to win money to th

A chemokine gradient does not move a leukocyte anywhere. It only tells one that has already stopped which way to go. That sentence is the whole map. Trafficking is a four-step cascade and the steps a

Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli